Young-onset Dementia Following Chronic Abuse of Amphetamine-type Stimulants

Overview

Journal Pak J Med Sci

Specialty General Medicine

Date 2024 Mar 28

PMID 38545016

Authors

Sultan H Alamri

Affiliations

Soon will be listed here.

Abstract

Young-onset dementia (YOD) is influenced by various risk factors, including substance abuse. In this report, we present the case of a 54-year-old man who developed YOD following prolonged abuse of amphetamine-type stimulants. The patient exhibited insidious cognitive decline over a three-year period before seeking medical attention. Neuroimaging revealed atrophy of the temporal lobe, suggesting a connection between amphetamine-induced neurotoxicity and the cognitive abnormalities observed in the patient condition. Our case highlights the importance of considering amphetamine-type stimulants as potential risk factors for YOD and emphasizes the need to recognize cognitive impairment resulting from substance abuse. Additionally, we look into relevant literature to provide further context and insights.

References

Zhang X, Tian Y, Wang Z, Ma Y, Tan L, Yu J . The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention. J Prev Alzheimers Dis. 2021; 8(3):313-321. DOI: 10.14283/jpad.2021.15. View

Ersche K, Clark L, London M, Robbins T, Sahakian B . Profile of executive and memory function associated with amphetamine and opiate dependence. Neuropsychopharmacology. 2005; 31(5):1036-47. PMC: 1867318. DOI: 10.1038/sj.npp.1300889. View

Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I . Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. J Prev Alzheimers Dis. 2021; 8(3):371-386. DOI: 10.14283/jpad.2021.23. View

Tzeng N, Chien W, Chung C, Chang H, Kao Y, Liu Y . Association between amphetamine-related disorders and dementia-a nationwide cohort study in Taiwan. Ann Clin Transl Neurol. 2020; 7(8):1284-1295. PMC: 7448166. DOI: 10.1002/acn3.51113. View

Quach C, Hommet C, Mondon K, Lauvin M, Cazals X, Cottier J . Early-onset dementias: Specific etiologies and contribution of MRI. Diagn Interv Imaging. 2013; 95(4):377-98. DOI: 10.1016/j.diii.2013.07.009. View

Nordstrom P, Nordstrom A, Eriksson M, Wahlund L, Gustafson Y . Risk factors in late adolescence for young-onset dementia in men: a nationwide cohort study. JAMA Intern Med. 2013; 173(17):1612-8. DOI: 10.1001/jamainternmed.2013.9079. View

Ornstein T, Iddon J, Baldacchino A, Sahakian B, London M, Everitt B . Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology. 2000; 23(2):113-26. DOI: 10.1016/S0893-133X(00)00097-X. View

Shukla M, Vincent B . Methamphetamine abuse disturbs the dopaminergic system to impair hippocampal-based learning and memory: An overview of animal and human investigations. Neurosci Biobehav Rev. 2021; 131:541-559. DOI: 10.1016/j.neubiorev.2021.09.016. View

Wang T, Fan T, Bao Y, Li X, Liang C, Wang R . Pattern and related factors of cognitive impairment among chronic methamphetamine users. Am J Addict. 2017; 26(2):145-151. DOI: 10.1111/ajad.12505. View

10.

Loi S, Cations M, Velakoulis D . Young-onset dementia diagnosis, management and care: a narrative review. Med J Aust. 2023; 218(4):182-189. PMC: 10952480. DOI: 10.5694/mja2.51849. View

11.

Ferrucci M, Limanaqi F, Ryskalin L, Biagioni F, Busceti C, Fornai F . The Effects of Amphetamine and Methamphetamine on the Release of Norepinephrine, Dopamine and Acetylcholine From the Brainstem Reticular Formation. Front Neuroanat. 2019; 13:48. PMC: 6524618. DOI: 10.3389/fnana.2019.00048. View